MedTrace Logo

Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial

NCT05320926 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3744

Last updated 2024-10-22

No results posted yet for this study

Summary

Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.

Conditions

  • Ischemic Heart Disease

Interventions

DRUG

Clopidogrel monotherapy

Patients will be randomized to stop aspirin and maintain clopidogrel after short-term DAPT.

DRUG

Aspirin monotherapy

Patients will be randomized to stop clopidogrel and maintain aspirin after short-term DAPT.

DEVICE

zotarolimus-eluting stent (Resolute Onyx ®)

zotarolimus-eluting stent (Resolute Onyx ®)

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Byeong-Keuk Kim · Severance Cardiovascular Hospital, Yonsei University Health System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2028-07-10
Completion
2028-07-10

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320926 on ClinicalTrials.gov